Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COMMENTARY
COMMENTARY
- “Drug Discovery Support Organization” Faces Doubts: Can It Pick Winners?
November 28, 2011
- Perpetuation of Premium for New Drug Development Faces Hurdles
November 14, 2011
- Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs
November 14, 2011
- Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
- Pinning Hope on Academia in Seeking a Radical Cure for AD
October 10, 2011
- New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
October 3, 2011
- Discussions on Amendment of PAL Now in Final Stages
October 3, 2011
- Korosho Revises GL for Drafting, Distributing Drug Safety Information
September 5, 2011
- Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
August 29, 2011
- Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
August 8, 2011
- Current Promising Drug Candidates with a New Mode of Action
August 8, 2011
- Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
July 18, 2011
- Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
July 4, 2011
- Era of Competition Dawns in Market for AD Treatments
June 27, 2011
- Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
June 20, 2011
- Return to Full-bore Growth Strategy Risky for Taiyo Pharm
June 13, 2011
- Why the Same Mistake Repeated? -MSD's Promotion Code Violations
June 6, 2011
- GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
June 6, 2011
- Effects of Changes to Accelerate Approval to Be Seen from November
May 30, 2011
- Japan's Most Admired Pharma Companies in 2010
April 4, 2011
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…